|
| Number of CNV-ME, mean ± SD | 37.5 ± 6.8 |
| 12 months | 9.3 ± 2.0 |
| 24 months | 8.0 ± 2.0 |
| 36 months | 7.2 ± 2.1 |
| 48 months | 6.9 ± 1.9 |
| 60 months | 6.1 ± 2.2 |
| Missed CNV-ME, mean ± SD | 1.6 ± 1.7 |
| Due to disease, n (%) | 111 (59.0) |
| Due to unknown reasons, n (%) | 77 (41.0) |
| Patients with at least 1, n (%) | 78 (66.7) |
| Patients with more than 1, n (%) | 49 (41.9) |
| Number of injections, mean ± SD | 21.7 ± 12.4 |
| 12 months | 6.0 (2.4) |
| 24 months | 4.2 (3.1) |
| 36 months | 3.7 (3.1) |
| 48 months | 4.0 (3.7) |
| 60 months | 3.8 (3.7) |
| Missed injections, n | 27 |
| Patients with at least 1, n (%) | 25 (21.4) |
| Patients with more than 1, n (%) | 2 (1.7) |
| Treatment suspensions, mean ± SD | 5.3 ± 3.0 |
| Due to medical indication, n (%) | 562 (90.8) |
| Without medical indication, n (%) | 57 (9.2) |
| Treatment reinitiations, mean ± SD | 4.7 ± 3.1 |
| Patients needing further treatment at the end of follow-up, n (%) | 51 (43.6) |
| Development of atrophy, n (%) | 83 (70.9) |
| During treatment, n (%) | 52 (62.7) |
| During suspension with medical indication, n (%) | 31 (37.3) |
| Development of RPE tear, n (%) | 9 (7.7) |
| During treatment, n (%) | 8 (88.9) |
| During suspension with medical indication, n (%) | 1 (11.1) |
| Development of subretinal fibrosis, n (%) | 75 (68.5) |
| During treatment, n (%) | 61 (81.3) |
| During suspension with medical indication, n (%) | 14 (18.7) |
| Sudden massive hemorrhages | |
| Episodes during treatment, n (%) | 24 (51.1) |
| Episodes during suspension with medical indication, n (%) | 23 (48.9) |
| Patients with at least 1 episode, n (%) | 38 (32.5) |
| Patients with more than 1 episode, n (%) | 9 (7.7) |
|
